IL90427A - Peptide-containing pharmaceutical compositions having use for treatment of neuropsychiatric deficits - Google Patents
Peptide-containing pharmaceutical compositions having use for treatment of neuropsychiatric deficitsInfo
- Publication number
- IL90427A IL90427A IL9042789A IL9042789A IL90427A IL 90427 A IL90427 A IL 90427A IL 9042789 A IL9042789 A IL 9042789A IL 9042789 A IL9042789 A IL 9042789A IL 90427 A IL90427 A IL 90427A
- Authority
- IL
- Israel
- Prior art keywords
- thr
- ala
- formula
- cys
- linear peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 61
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 11
- 230000006735 deficit Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 206010027175 memory impairment Diseases 0.000 claims abstract description 6
- 208000026139 Memory disease Diseases 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 3
- CUTPSEKWUPZFLV-WISUUJSJSA-N Thr-Cys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(O)=O CUTPSEKWUPZFLV-WISUUJSJSA-N 0.000 claims 4
- 239000000935 antidepressant agent Substances 0.000 claims 3
- 230000001519 thymoleptic effect Effects 0.000 claims 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 26
- 230000027455 binding Effects 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 abstract description 8
- 201000004681 Psoriasis Diseases 0.000 abstract description 6
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 abstract description 4
- 208000019022 Mood disease Diseases 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 108010071384 Peptide T Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- -1 Thr amide Chemical class 0.000 description 2
- 108070000030 Viral receptors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- KQDPSIMTNJSDOM-UHFFFAOYSA-N benzene styrene Chemical compound C1=CC=CC=C1.C1=CC=CC=C1.C=CC1=CC=CC=C1 KQDPSIMTNJSDOM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920006026 co-polymeric resin Polymers 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- IWHCAJPPWOMXNW-LYKMMFCUSA-N peptide t Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 IWHCAJPPWOMXNW-LYKMMFCUSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19987388A | 1988-05-27 | 1988-05-27 | |
| US28555988A | 1988-12-16 | 1988-12-16 | |
| US07/352,313 US5063206A (en) | 1988-12-16 | 1989-05-16 | Compositions having use as treatment of neuropsychiatric deficits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL90427A true IL90427A (en) | 1994-10-07 |
Family
ID=27394077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9042789A IL90427A (en) | 1988-05-27 | 1989-05-26 | Peptide-containing pharmaceutical compositions having use for treatment of neuropsychiatric deficits |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0415999B1 (de) |
| JP (2) | JPH0618777B2 (de) |
| AT (1) | ATE168698T1 (de) |
| AU (1) | AU620107B2 (de) |
| CA (1) | CA1336677C (de) |
| DE (1) | DE68928752T2 (de) |
| IL (1) | IL90427A (de) |
| WO (1) | WO1989012067A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242564B1 (en) * | 1986-06-03 | 2001-06-05 | Candace B. Pert | Treatment of tropical spastic paresis with peptide T |
| US5189022A (en) * | 1988-05-27 | 1993-02-23 | The United States Of America As Represented By The Secretary Of Health And Human Services | Composition for the treatment of chronic fatigue syndrome |
| DK31991D0 (da) * | 1991-02-25 | 1991-02-25 | Carlbiotech Ltd As | Peptid og farmaceutisk praeparat indeholdende et saadant peptid |
| ZA932233B (en) * | 1992-03-27 | 1994-09-29 | Peptide Technology Ltd | Peptide T and related peptides in the treatment of inflammation including multiple sclerosis |
| US6011014A (en) * | 1992-03-27 | 2000-01-04 | Advanced Immunit, Inc. | Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis |
| DK0635027T3 (da) * | 1992-03-27 | 2000-10-02 | Advanced Immunit T Inc | Peptid T og beslægtede peptider til behandling af inflammation, herunder dissemineret sclerose |
| DK0871466T3 (da) * | 1993-09-24 | 2004-08-16 | Advanced Immuni T Inc | Lineære og cykliske peptider til behandling eller forebyggelse af eksem/dermatitis |
| AU7735194A (en) * | 1993-09-24 | 1995-04-10 | Peptide Technology Limited | Treatment or prevention of Crohn's disease and/or ulcerative colitis |
| JP3863829B2 (ja) | 2002-08-27 | 2006-12-27 | ペンタックス株式会社 | ズームレンズ鏡筒の繰出カム機構及び繰出カム機構 |
| JP2004085932A (ja) | 2002-08-27 | 2004-03-18 | Pentax Corp | ズームレンズ鏡筒の繰出カム機構及び繰出カム機構 |
| US7058293B2 (en) | 2002-08-27 | 2006-06-06 | Pentax Corporation | Optical element retracting mechanism for a retractable lens |
| US7085486B2 (en) | 2002-08-27 | 2006-08-01 | Pentax Corporation | Lens barrel incorporating a rotatable ring |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5921613A (ja) * | 1982-07-28 | 1984-02-03 | Takeda Chem Ind Ltd | 直腸投与製剤 |
| ATE96450T1 (de) * | 1986-06-03 | 1993-11-15 | Us Commerce | Kleine peptide, die die bindung an t-4-rezeptoren inhibieren und als immunogene wirken. |
| AU7544987A (en) * | 1986-06-03 | 1988-01-11 | Pert, C.B. | Small peptides which inhibit binding to t-4 receptors |
| US4804651A (en) * | 1987-06-09 | 1989-02-14 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of psoriasis |
| PT90657B (pt) * | 1988-05-27 | 1995-03-01 | Ortho Pharma Corp | Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora |
-
1989
- 1989-05-25 WO PCT/US1989/002205 patent/WO1989012067A1/en not_active Ceased
- 1989-05-25 EP EP89906251A patent/EP0415999B1/de not_active Expired - Lifetime
- 1989-05-25 AU AU36936/89A patent/AU620107B2/en not_active Expired
- 1989-05-25 AT AT89906251T patent/ATE168698T1/de not_active IP Right Cessation
- 1989-05-25 JP JP1506059A patent/JPH0618777B2/ja not_active Expired - Lifetime
- 1989-05-25 DE DE68928752T patent/DE68928752T2/de not_active Expired - Fee Related
- 1989-05-26 IL IL9042789A patent/IL90427A/en unknown
- 1989-05-29 CA CA000600999A patent/CA1336677C/en not_active Expired - Fee Related
-
1993
- 1993-09-16 JP JP5230549A patent/JP3011837B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0415999B1 (de) | 1998-07-22 |
| DE68928752D1 (de) | 1998-08-27 |
| EP0415999A4 (en) | 1991-10-16 |
| CA1336677C (en) | 1995-08-15 |
| WO1989012067A1 (en) | 1989-12-14 |
| DE68928752T2 (de) | 1998-12-03 |
| AU620107B2 (en) | 1992-02-13 |
| ATE168698T1 (de) | 1998-08-15 |
| EP0415999A1 (de) | 1991-03-13 |
| JPH03502928A (ja) | 1991-07-04 |
| JPH0618777B2 (ja) | 1994-03-16 |
| AU3693689A (en) | 1990-01-05 |
| JPH06228001A (ja) | 1994-08-16 |
| JP3011837B2 (ja) | 2000-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SWANSON et al. | Myoclonus—a report of 67 cases and review of the literature | |
| US5063206A (en) | Compositions having use as treatment of neuropsychiatric deficits | |
| DE69311427T2 (de) | Synthetische Polypeptide als Inhibitoren von HIV-1 | |
| IL90427A (en) | Peptide-containing pharmaceutical compositions having use for treatment of neuropsychiatric deficits | |
| WO1997031002A9 (en) | Fused pyrrolo(2,3-c)carbazole-6-ones which potentiate activity of gamma interferon | |
| ATE87484T1 (de) | Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| AU663875B2 (en) | Compositons for the treatment of chronic fatigue syndrome | |
| McComas et al. | Motoneurone dysfunction in patients with hemiplegie atrophy | |
| FI96865C (fi) | Menetelmä terapeuttisesti käyttökelpoisen, olennaisesti puhtaan polypeptidin valmistamiseksi | |
| Naftchi | Functional restoration of the traumatically injured spinal cord in cats by clonidine | |
| JPH06247874A (ja) | ほにゅう動物の熱帯けいれん性不全マヒおよびｈｔｌｖ−１伝染患者の神経衝動および認識性挙動の治療方法 | |
| US5534495A (en) | Treatment of non-HIV neuropathic pain syndromes | |
| US5248667A (en) | Method of treating psoriasis using synthetic peptide compositions | |
| RU2290197C2 (ru) | Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения | |
| EP1075270B1 (de) | Kurzes peptid zur behandlung neurodegenerativer erkrankungen | |
| JP3520084B2 (ja) | 多発性硬化症を含めた炎症の治療におけるペプチドｔ及びその関連ペプチド類 | |
| RU2288716C2 (ru) | Нейротропные аналоги такролимуса | |
| RS40804A (sr) | Postupak za reagovanje alkaloida i upotreba proizvoda reakcije za dobijanje medikamenata | |
| Lebedyeva et al. | Ionic conjugates of lidocaine and sweeteners as better tasting local anesthetics for dentistry | |
| WO1999018123A1 (fr) | Utilisation des bloqueurs des canaux potassium neuronaux et lymphocytaires dans le traitement des maladies neurologiques d'origine immunitaire | |
| CN120303285A (zh) | 一种多肽及其应用 | |
| Bennett | The introduction of curare into clinical medicine: present and potential usefulness | |
| JP2000500156A (ja) | ヒルから得られる抗ウイルス性単離物 | |
| US3380887A (en) | Use of butyrolactam for treating motion sickness |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |